Get started
Author

Nobuyuki Tatsumi

ORCID: 0009-0006-6114-7534
Observed ORCID: 0009-0006-6114-7534
OpenAlex ID: A5122767906
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
2026 · Chinatsu Nishioka, Yuki Tahata, et al. · PLoS ONE · 2
PDF
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2026 · Yu Sato, Takahiro Kodama, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Delayed Bile Duct Injury Preceded by Sepsis After Biliary Cooling–Assisted Ablation of Hilar Hepatocellular Carcinoma
2026 · Chihiro Tarumi, Yuki Tokuda, et al. · ACG Case Reports Journal
Ciliated Hepatic Foregut Cyst With Clustered Echogenic Foci: An Incidental Finding on Health Screening
2026 · Yuka Miyoshi, Akira Nishio, et al. · The American Journal of Gastroenterology
Works count: 4
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type